Omega-3 Fatty Acids to Combat Sarcopenia

Mayo Clinic

Status and phase: Completed; Phase 1

Conditions: Sarcopenia

Treatments: Drug: Omega-3 fatty acids

Study type: Interventional

Funder types: Other

Identifiers

NCT02103842

14-000639

Details and patient eligibility

About

The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.

Enrollment: 24 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-35 or 65-85 years

Exclusion criteria

1. Current use of omega-3 nutritional supplements
2. Fasting plasma glucose ≥126 mg/dL
3. Active coronary artery disease
4. Participation in structured exercise (>3 times per week for 30 minutes or longer)
5. Smoking
6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)
7. Renal failure (serum creatinine > 1.5mg/dl)
8. Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L)
9. Anti-coagulant therapy (warfarin/heparin)
10. INR >3
11. Use of systemic glucocorticoids
12. Chronic use of NSAIDS or aspirin
13. Pregnancy or breastfeeding
14. Alcohol consumption greater than 2 glasses/day
15. Hypothyroidism
16. Fish or shellfish allergy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Omega-3 fatty acids

Experimental group

Description:

Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months

Treatment:

Drug: Omega-3 fatty acids